{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:18:06Z","timestamp":1779376686737,"version":"3.53.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This systematic review and meta-analysis investigated the relationship between somatic <jats:italic>TP53<\/jats:italic> oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of <jats:italic>TP53<\/jats:italic> variants was assessed. We conducted searches in multiple databases. We assessed bias risk using a modified version of the Quality in Prognosis Studies tool, and the certainty of evidence was evaluated following the principles of the GRADE approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and conclusion<\/jats:title><jats:p>This study encompassed 23 papers involving 2,555 patients, out of which 716 had reported oncogenic variants. <jats:italic>TP53<\/jats:italic> oncogenic variants were associated with a reduced likelihood of 1-year survival (OR 0.52, 95% CI 0.29\u20130.94). However, our analysis did not reveal any significant impact of <jats:italic>TP53<\/jats:italic> variants on overall survival, progression-free survival, or 2-year survival. Therefore, this comprehensive analysis demonstrates that the presence of genetic variants in <jats:italic>TP53<\/jats:italic> does not provide useful information for the prognosis of glioblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42021289496.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1490246","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:47:52Z","timestamp":1734504472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["TP53 oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Diego","family":"Esperante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena Daza","family":"Galicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalu Gabriel","family":"Rivas-Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Cacho-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Trejo-Becerril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taja-Chayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orwa","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alberto","family":"Carlos-Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Wegman-Ostrosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence-based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J Neuro Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Loui","year":"2016","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","article-title":"Cancer incidence, patterns, and genotype\u2013phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study","volume":"22","author":"de Andrade","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1158\/1078-0432.CCR-08-2801","article-title":"Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients","volume":"15","author":"Felsberg","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdac096","article-title":"Molecular alterations associated with improved outcome in patients with glioblastoma treated with tumor-treating fields","volume":"4","author":"Pandey","year":"2022","journal-title":"Neuro Oncol Adv"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and Genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/gutjnl-2015-310888","article-title":"The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis","volume":"66","author":"Fisher","year":"2017","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of clinical genome resource (ClinGen), Cancer Genomics consortium (CGC), and variant interpretation for Cancer consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing Bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD013316","DOI":"10.1002\/14651858.CD013316.pub2","article-title":"Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide","volume":"3","author":"McAleenan","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jrsm.1266","article-title":"Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests","volume":"9","author":"Debray","year":"2018","journal-title":"Res Synth Methods"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"107146","DOI":"10.1016\/j.clineuro.2022.107146","article-title":"Clinical and survival characteristics of primary and secondary gliosarcoma patients","volume":"214","author":"Amer","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1440-1789.2009.01081.x","article-title":"Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features","volume":"30","author":"Benito","year":"2010","journal-title":"Neuropathology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3171\/JNS-07\/09\/0586","article-title":"Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status","volume":"107","author":"Clark","year":"2007","journal-title":"J Neurosurg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"vdab 050","DOI":"10.1093\/noajnl\/vdab050","article-title":"The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma","volume":"3","author":"Dono","year":"2021","journal-title":"Neurooncol Adv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1158\/1078-0432.CCR-13-0017","article-title":"Long-term survival in primary glioblastoma with versus without isocitrate de-hydrogenase mutations","volume":"19","author":"Hartmann","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5114\/PJP.2013.39335","article-title":"Association of loss of heterozygosity with shorter survival in primary glioblastoma patients","volume":"4","author":"Jesionek-Kupnicka","year":"2013","journal-title":"Polish J Pathol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5114\/aoms.2017.69374","article-title":"Basic research miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients","volume":"15","author":"Jesionek-Kupnicka","year":"2019","journal-title":"Arch Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3389\/fonc.2019.01433","article-title":"Gene expression profiling stratifies IDH-Wildtype glioblastoma with distinct prognoses","volume":"9","author":"Liu","year":"2019","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.humpath.2018.12.004","article-title":"Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling","volume":"86","author":"McNulty","year":"2019","journal-title":"Hum Pathol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.25637","article-title":"Benefits of interferon-\u03b2 and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter","volume":"117","author":"Motomura","year":"2010","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"106636","DOI":"10.1016\/j.intimp.2020.106636","article-title":"Establishment and validation of an immune-based prognostic score model in glioblastoma","volume":"85","author":"Qin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12032-018-1119-2","article-title":"Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization","volume":"35","author":"Sim","year":"2018","journal-title":"Med Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"654727","DOI":"10.1155\/2014\/654727","article-title":"IDH1\/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients","volume":"2014","author":"Stancheva","year":"2014","journal-title":"Biomed Res Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.neo.2020.10.010","article-title":"Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma","volume":"22","author":"Stasik","year":"2020","journal-title":"Neoplasia"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/jclinpath-2014-202173","article-title":"Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study","volume":"67","author":"Tabone","year":"2014","journal-title":"J Clin Pathol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","article-title":"Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide","volume":"21","author":"Wang","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","article-title":"Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network","volume":"27","author":"Weller","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41379-021-00778-x","article-title":"Molecular landscape of IDH-mutant primary astrocytoma grade IV\/glioblastomas","volume":"34","author":"Wong","year":"2021","journal-title":"Mod Pathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.radonc.2018.11.025","article-title":"Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma \u2013 Radiogenomic approach for precision medicine","volume":"131","author":"Yang","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"vdac 002","DOI":"10.1093\/noajnl\/vdac002","article-title":"Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma","volume":"4","author":"Yang","year":"2022","journal-title":"Neurooncol Adv"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-020-0251-x","article-title":"Context is everything: extrinsic signalling and gain-of-function p53 mutants","volume":"6","author":"Amelio","year":"2020","journal-title":"Cell Death Discov"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.3390\/cancers13215362","article-title":"TP53 mutation is a prognostic factor in lower grade glioma and may influence chemotherapy efficacy","volume":"13","author":"Noor","year":"2021","journal-title":"Cancers"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10072-012-1257-9","article-title":"Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O (6)-methylguanine DNA-methyltransferase","volume":"34","author":"Wang","year":"2013","journal-title":"Neurol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/nar\/gky1314","article-title":"Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket","volume":"47","author":"Pradhan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1021\/acs.chemrev.3c00131","article-title":"Targeting biomolecular condensation and protein aggregation against cancer","volume":"123","author":"Silva","year":"2023","journal-title":"Chem Rev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"100820","DOI":"10.1016\/j.isci.2020.100820","article-title":"Oncogenic gain of function in glioblastoma is linked to mutant p53 amyloid oligomers","volume":"23","author":"Pedrote","year":"2020","journal-title":"iScience"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1039\/d1sc01739j","article-title":"Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands","volume":"12","author":"Petronilho","year":"2021","journal-title":"Chem Sci"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/biomedicines11071879","article-title":"MDM2 inhibition in the treatment of glioblastoma: from concept to clinical investigation","volume":"11","author":"Pellot Ortiz","year":"2023","journal-title":"Biomedicines"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/cancers12030654","article-title":"MK2 inhibition induces p53-dependent senescence in glioblastoma cells","volume":"12","author":"Phoa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.clineuro.2016.05.002","article-title":"Clinical prognostic factors in adults with astrocytoma: historic cohort","volume":"146","author":"Wegman-Ostrosky","year":"2016","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1490246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:47:55Z","timestamp":1734504475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1490246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":48,"alternative-id":["10.3389\/fneur.2024.1490246"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1490246","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1490246"}}